Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IQVIA HOLDINGS INC.

(IQV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

IQVIA Launches New Grants/Funding Management Module for Its Orchestrated Customer Engagement Platform

11/18/2021 | 08:00am EST

IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the launch of Grants and Funding Management, new module within the Orchestrated Customer Engagement (OCE) solutions portfolio. From grant submission to payment processing and closeout, IQVIA Grants and Funding Management provides life sciences companies with a solution to efficiently manage and oversee their global strategic giving programs.

“IQVIA Technologies is excited to announce our latest offering, built to transform funding request management for life sciences companies through its advanced user interface (UI) and automated end-to-end workflows,” said Michael Utell, vice president, IQVIA Commercial Compliance. “For over 15 years we have been at the forefront of grants management, driven by our deep understanding of its impact and intricacy. Expanding our focus to user experience and outcomes is essential in addressing the market needs.”

Built on IQVIA’s Orchestrated Customer Engagement Platform, the Grants and Funding Management module automates and streamlines the end-to-end grants and funding requests for medical education, charitable donations, sponsorships, patient education and other giving programs. From the funding application, approval, and review, through to payment and transparency reporting, this new module allows life sciences companies to accelerate funding requests, eliminate errors, monitor compliance, track payments, and demonstrate the impact of giving programs globally.

“With this launch, IQVIA has further expanded in the engagement management space, transforming grants and funding through streamlined workflows and automated processes. Prior to this launch, there was a need for a global grants solution focused on user experience and outcomes. Leveraging unparalleled compliance expertise, and insight into how quickly regulations change, IQVIA’s newest platform is built to evolve with industry needs, improving business efficiencies,” said Mike Townsend, IDC analyst.

For more information about IQVIA’s latest Grants and Funding Management solution, please visit www.iqvia.com/grants.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 77,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, to advance their path toward cures. To learn more, visit www.iqvia.com.


ę Business Wire 2021
All news about IQVIA HOLDINGS INC.
01/27IQVIA : Leslie Wims Morris Joins IQVIA Board of Directors - Form 8-K
PU
01/27IQVIA HOLDINGS INC. : Change in Directors or Principal Officers, Regulation FD Disclosure,..
AQ
01/26Sheila A. Stamps Joins IQVIA Board of Directors
BU
01/26IQVIA Holdings Inc. Appoints Sheila A. Stamps to Board of Directors
CI
01/24Leslie Wims Morris Joins IQVIA Board of Directors
BU
01/24Leslie Wims Morris Joins IQVIA Board of Directors
CI
01/04Travere Therapeutics Names Jula Inrig Chief Medical Officer
MT
01/04Evercore ISI Adjusts Price Target for IQVIA Holdings to $350 From $320, Maintains Outpe..
MT
2021Mizuho Securities Adjusts IQVIA Holdings PT to $300 From $290, Maintains Buy Rating
MT
2021IQVIA : OneKey Powers Precision Targeting
PU
More news
Analyst Recommendations on IQVIA HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2021 13 830 M - -
Net income 2021 922 M - -
Net Debt 2021 10 634 M - -
P/E ratio 2021 49,0x
Yield 2021 -
Capitalization 44 321 M 44 321 M -
EV / Sales 2021 3,97x
EV / Sales 2022 3,61x
Nbr of Employees 77 000
Free-Float 74,0%
Chart IQVIA HOLDINGS INC.
Duration : Period :
IQVIA Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 232,00 $
Average target price 304,59 $
Spread / Average Target 31,3%
EPS Revisions
Managers and Directors
Ari Bousbib Chairman, President & Chief Executive Officer
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
W. Richard Staub President-Research & Development Solutions
Kevin C. Knightly President-Technology & Commercial Solutions
Sector and Competitors
1st jan.Capi. (M$)
IQVIA HOLDINGS INC.-17.77%44 321
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892
CELLTRION, INC.-25.51%17 086